Status:
RECRUITING
Computational Drug Repurposing for All EBS Cases
Lead Sponsor:
Joyce Teng
Conditions:
Epidermolysis Bullosa
Healthy
Eligibility:
All Genders
Brief Summary
The study will compare gene expression differences between blistered and non-blistered skin from individuals with all subtypes of EB, as well as normal skin from non-EB subjects. State of the art comp...
Detailed Description
Although gene, cell, and protein-based therapies are in development for patients suffering from all subtypes of epidermolysis bullosa (EB), new pharmacological treatments are in dire need. Characteriz...
Eligibility Criteria
Inclusion
- Subjects of all ages
- Diagnosis of all subtypes of EB subjects
- Healthy, non-EB subjects
- Ability to complete study visit to collect tissue and blood specimen
Exclusion
- Pregnancy, breast feeding
- Prior history of liver disease
- Serious known concurrent medical illness or infection, which could potentially present a safety risk and/or prevent tissue collection from subjects
Key Trial Info
Start Date :
November 28 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT03269474
Start Date
November 28 2017
End Date
December 31 2024
Last Update
February 13 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pediatric Dermatology Clinic at Stanford Children's Hospital
Palo Alto, California, United States, 94304